Atsena Therapeutics

  • BioTech/Drugs
  • Durham NC
  • 27 employees
Employee Directory Email Format Management Departments
Get Full Info

Company Overview

Website
atsenatx.com
Phone
(352) 273-9342
Employees
27
Industry
BioTech/Drugs
More Details

Financials & Stats

Revenue

$10B

More Financials

Recent News & Media

Atsena Therapeutics Announces Alignment with FDA on

  • Jul 9, 2025
  • globenewswire.com

Atsena Therapeutics Announces Positive Clinical Data from Part A of Phase I/II Trial Evaluating ATSN-201 Gene Therapy to Treat X-linked Retinoschisis (XLRS)

  • May 19, 2025
  • globenewswire.com

Atsena eye disease gene therapy hits safety goals, closes retinal splits in phase 1/2

  • May 19, 2025
  • fiercebiotech.com

Atsena Therapeutics to Present at May Scientific Conferences

  • Apr 29, 2025
  • globenewswire.com

FDA grants RMAT designation to Atsena Therapeutics' gene therapy for XLRS

  • Apr 16, 2025
  • ophthalmologytimes.com

Atsena Therapeutics Granted U.S. FDA Regenerative Medicine

  • Apr 15, 2025
  • globenewswire.com

Who is Atsena Therapeutics

Atsena Therapeutics is a clinical-stage gene therapy company situated in Durham, North Carolina. The company employs 27 people. Atsena Therapeutics specializes in developing innovative treatments for inherited forms of blindness. Their current clinical programs include ATSN-201 for X-linked retinoschisis (XLRS) and ATSN-101 for Leber congenital amaurosis (LCA1). ATSN-201 utilizes a novel spreading capsid AAV.SPR, and the company is preparing to launch The Lighthouse Study, a Phase I/II clinical trial to evaluate its effectiveness in treating XLRS. ATSN-301, another proprietary asset, is a dual AAV vector-based gene therapy aimed at preventing blindness caused by MYO7A-associated Usher syndrome (USH1B). Atsena Therapeutics has demonstrated promising results with ATSN-101, showing that it is well-tolerated and produces clinically meaningful improvements in vision six months after treatment in patients with LCA1. For more information, visit www.atsenatx.com.

Company Leadership

Kenji Fujita

Chief Medical Officer

Phone Email

Companies Similar to Atsena Therapeutics

Analyze industry trends and opportunities by examining competitors and companies comparable to Atsena Therapeutics, including their performance metrics, financials, growth dynamics, and competitive benchmarks.

Company Name Revenue Number of Employees Location Founded in

Astria Therapeutics Inc

 10M 59 Boston, MA

Eleven Biotherapeutics

 10M 27 Cambridge, MA 2010

Interleukin Genetics

 10M 23 Waltham, MA 1999

MetaStat

 10M 2 Boston, MA

Yield10 Bioscience

 10M 46 Woburn, MA
View More Companies

FAQ

What is the location of Atsena Therapeutics's headquarters?
The headquarters of Atsena Therapeutics are situated at 701 W Main St, Suite 200, Durham NC
What is Atsena Therapeutics's phone number?
Atsena Therapeutics's contact number is (352) 273-9342.
What is Atsena Therapeutics's official website?
The official website of Atsena Therapeutics can be found at atsenatx.com.
What is Atsena Therapeutics's current revenue?
As of August 2021, Atsena Therapeutics's annual revenue reached $10B.
How many employees does Atsena Therapeutics currently have?
Atsena Therapeutics employs approximately 27+ people as of August 2021
Which industries is Atsena Therapeutics primarily operating in?
Atsena Therapeutics operates in the following industries: Biotechnology, Pharmaceutical, Therapeutics
Who is the Chief Medical Officer of Atsena Therapeutics?
Atsena Therapeutics's Chief Medical Officer is Kenji Fujita

Employee Directory

Key Employees

Dana Elmore

Senior Project Manager

Phone Email

Rachel Smith

Vice President of Regulatory

Phone Email

Miranda Harrison

Customer Service Representative/ Data Entry / IT Support Specialists

Phone Email